Pan-RAF:MEK Molecular Glues Take Center Stage.

IF 29.7 1区医学 Q1 ONCOLOGY Cancer discovery Pub Date : 2024-07-01 DOI:10.1158/2159-8290.CD-24-0539

Matthew J Hangauer, Jorge Silvio Gutkind, Fleur M Ferguson

引用次数: 0

Abstract

In this issue, Ryan and colleagues describe the preclinical development of a pan-RAF:MEK molecular glue with superior efficacy, brain penetrance, and tolerability in xenograft models of Ras/Raf/MAPK pathway-driven tumors. See related article by Ryan et al., p. 1190 (1).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

泛 RAF:MEK 分子胶占据中心位置。

在本期杂志中，Ryan 及其同事介绍了泛 RAF:MEK 分子胶的临床前开发情况，该分子胶在 Ras/Raf/MAPK 通路驱动的肿瘤异种移植模型中具有卓越的疗效、脑穿透性和耐受性。请参见 Ryan 等人的相关文章，第 1190 页（1）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.

期刊最新文献

Trem2-expressing multinucleated giant macrophages are a biomarker of good prognosis in head and neck squamous cell carcinoma NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells. Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities.